EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors

Milind Javle, Gentry King, Kristen Spencer iD, Mitesh J Borad

The Oncologist · 02.11.2023 · 28 (11) · 928-943

DOI: 10.1093/oncolo/oyad149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 30.06.2023. Verfasst von Milind Javle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiho Oncology, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. This review summarizes the preclinical and clinical development of futibatinib, an irreversible FGFR1-4 inhibitor. Futibatinib stands out among FGFR inhibitors because of its covalent binding mechanism and low susceptibility to acquired resistance. Preclinical data indicated robust activity of futibatinib against acquired resistance mutations in the FGFR kinase domain. In early-phase studies, futibatinib showed activity in cholangiocarcinoma, and gastric, urothelial, breast, central nervous system, and head and neck cancers harboring various FGFR aberrations. Exploratory analyses indicated clinical benefit with futibatinib after prior FGFR inhibitor use. In a pivotal phase II trial, futibatinib demonstrated durable objective responses (42% objective response rate) and tolerability in previously treated patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. A manageable safety profile was observed across studies, and patient quality of life was maintained with futibatinib treatment in patients with cholangiocarcinoma. Hyperphosphatemia, the most common adverse event with futibatinib, was well managed and did not lead to treatment discontinuation. These data show clinically meaningful benefit with futibatinib in FGFR2-rearrangement-positive cholangiocarcinoma and provide support for further investigation of futibatinib across other indications. Future directions for this agent include elucidating mechanisms of resistance and exploration of combination therapy approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsHumansQuality of LifeBile Ducts, IntrahepaticProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1PyrazolesPyrimidinesPyrroles

Stichwörter der Autor:innen

FGFR inhibitorcholangiocarcinomaclinical trialsfibroblast growth factor receptorfutibatinibsafety

Substanzen

Protein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1futibatinibPyrazolesPyrimidinesPyrrolesFGFR1 protein, human

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Medical Oncology, University of Washington, Seattle, WA, USA.
  • Perlmutter Cancer Center of NYU Langone Health, New York, NY, USA.
  • NYU Grossman School of Medicine, New York University, New York, NY,USA.
  • Department of Oncology, Mayo Clinic Cancer Center, Phoenix, AZ,USA.

ORCID-Profile: Kristen Spencer

Förderung

  • Taiho Oncology, Inc

Zitieren

APA

Javle, M., King, G., Spencer, K., & Borad, M. J. (2023). Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors. The Oncologist, 28(11), 928-943. https://doi.org/10.1093/oncolo/oyad149

Vancouver

Javle M, King G, Spencer K, Borad MJ. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors. The Oncologist. 2023;28(11):928-943. doi:10.1093/oncolo/oyad149

BibTeX
@article{Javle2023,
  author = {Javle, Milind and King, Gentry and Spencer, Kristen and Borad, Mitesh J},
  title = {Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {11},
  pages = {928--943},
  doi = {10.1093/oncolo/oyad149}
}
Kostenlos starten →